Houtou Jianweiling Tablet Shows Promise in Treating Chronic Non-Atrophic Gastritis

Introduction

Chronic Non-Atrophic Gastritis (CNAG) is a prevalent digestive system disease characterized by inflammation of the stomach lining without atrophic changes. It affects a significant portion of the global population, with symptoms including abdominal pain, bloating, nausea, and indigestion. The condition is often caused by factors such as H. pylori infection, excessive alcohol use, and the routine use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Study Overview

The clinical trial aimed to evaluate the efficacy and safety of Houtou Jianweiling Tablet (HTJWT), a Chinese patent medicine, in treating CNAG. HTJWT is composed of six ingredients, including Hericium erinaceus mycelium, known for its therapeutic effects on gastrointestinal discomfort. The study compared HTJWT with Omeprazole, a standard treatment for CNAG, in a randomized, double-blind, parallel-controlled trial involving 240 patients.

Methods

Patients were randomly assigned to either the HTJWT group or the Omeprazole group and treated for 28 days. The primary efficacy indicators were the improvement rates of main clinical symptoms (gastralgia and gastric distension). The study adhered to ethical guidelines and was approved by relevant regulatory bodies.

Results

The trial found that HTJWT was non-inferior to Omeprazole in improving clinical symptoms of CNAG. The clinical effective rate was 91.1% in the HTJWT group and 91.0% in the Omeprazole group. HTJWT also showed a good safety profile, with no significant adverse events reported.

Conclusion

The study concludes that HTJWT is a safe and effective alternative treatment for CNAG, particularly for patients seeking natural remedies. Its efficacy in improving symptoms and its safety profile make it a promising option for managing this widespread condition. Further research is recommended to explore the long-term benefits and mechanisms of HTJWT in treating CNAG.